{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:50:36Z","timestamp":1744181436148,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-023-02533-5","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T23:46:36Z","timestamp":1674258396000},"page":"1541-1546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterizing risk factors for hospitalization for psoriasis patients"],"prefix":"10.1007","volume":"315","author":[{"given":"Claire E.","family":"Kovalchin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Kaffenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Trinidad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ty W.","family":"Gilkey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abena","family":"Minta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"Gudjonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin H.","family":"Kaffenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"issue":"6","key":"2533_CR1","first-page":"508","volume":"107","author":"J Nowowiejska","year":"2020","unstructured":"Nowowiejska J, Baran A, Flisiak I (2020) Psoriasis and cardiometabolic disorders. Dermatol Rev\/Przegl\u0105d Dermatologiczny 107(6):508\u2013520","journal-title":"Dermatol Rev\/Przegl\u0105d Dermatologiczny"},{"key":"2533_CR2","doi-asserted-by":"crossref","unstructured":"Asgari MM, Wu JJ, Gelfand JM, et al. Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996\u20132009. Pharmacoepidemiol Drug Saf [Internet]. 2013 Aug [cited 2020 Oct 17];22(8):842\u20139. Available from: \/pmc\/articles\/PMC3720770\/?report=abstract","DOI":"10.1002\/pds.3447"},{"key":"2533_CR3","doi-asserted-by":"crossref","unstructured":"Bhutani T, Wong JW, Bebo BF, Armstrong AW. Access to Health Care in Patients With Psoriasis and Psoriatic Arthritis Data From National Psoriasis Foundation Survey Panels [Internet]. Vol. 149, JAMA Dermatol. 2013. https:\/\/jamanetwork.com\/","DOI":"10.1001\/jamadermatol.2013.133"},{"issue":"4","key":"2533_CR4","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.jaad.2019.10.051","volume":"82","author":"BT Cheng","year":"2020","unstructured":"Cheng BT, Silverberg JI (2020) Predictors of hospital readmission in United States adults with psoriasis. J Am Acad Dermatol 82(4):902\u2013909","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2533_CR5","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/jid.2014.530","volume":"135","author":"FJ Dalgard","year":"2015","unstructured":"Dalgard FJ, Gieler U, Tomas-Aragones L et al (2015) The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol 135(4):984\u2013991","journal-title":"J Invest Dermatol"},{"key":"2533_CR6","doi-asserted-by":"crossref","unstructured":"Eppinga H, Poortinga S, Thio HB, et al. Prevalence and Phenotype of Concurrent Psoriasis and Inflammatory Bowel Disease. Inflamm Bowel Dis [Internet]. 2017 Oct 1 [cited 2020 Jul 21];23(10):1783\u20139. https:\/\/academic.oup.com\/ibdjournal\/article\/23\/10\/1783-1789\/4791654","DOI":"10.1097\/MIB.0000000000001169"},{"key":"2533_CR7","doi-asserted-by":"publisher","unstructured":"Kimball A, Gu\u00e9rin A, Tsaneva M, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatology Venereol [Internet]. 2011 Feb 1 [cited 2020 Jul 24];25(2):157\u201363. http:\/\/doi.wiley.com\/https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03730.x","DOI":"10.1111\/j.1468-3083.2010.03730.x"},{"issue":"4","key":"2533_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH et al (2019) Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 80(4):1029\u20131072","journal-title":"J Am Acad Dermatol"},{"key":"2533_CR9","doi-asserted-by":"publisher","unstructured":"Mw D, Hajdarbegovic BE. Psoriasis: Targets and Therapy Dovepress Drug-induced psoriasis: clinical perspectives. Psoriasis Targets Ther [Internet]. 2017 [cited 2020 Oct 11];7\u201387. Available from: http:\/\/dx.doi.org\/https:\/\/doi.org\/10.2147\/PTT.S126727","DOI":"10.2147\/PTT.S126727"},{"key":"2533_CR10","unstructured":"Pustular psoriasis: Management - UpToDate [Internet]. [cited 2020 Aug 26]. https:\/\/www.uptodate.com\/contents\/pustular-psoriasis-management?search=psoriasis treatment&topicRef=5666&source=see_link#H167785525"},{"issue":"3","key":"2533_CR11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"TD Rachakonda","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW (2014) Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 70(3):512\u2013516","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2533_CR12","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jaad.2015.02.1099","volume":"72","author":"J Vanderpuye-Orgle","year":"2015","unstructured":"Vanderpuye-Orgle J, Zhao Y, Lu J et al (2015) Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol 72(6):961-967.e5","journal-title":"J Am Acad Dermatol"},{"key":"2533_CR13","doi-asserted-by":"crossref","unstructured":"Zhang M, Markova A, Harp J, et al. Dermatology-specific and all-cause 30-day and calendar-year readmissions and costs for dermatologic diseases from 2010 to 2014. J Am Acad Dermatol [Internet]. 2019 Sep 1 [cited 2020 Dec 13];81(3):740\u20138. https:\/\/pubmed.ncbi.nlm.nih.gov\/31102603\/","DOI":"10.1016\/j.jaad.2019.05.023"},{"issue":"1","key":"2533_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.det.2011.08.002","volume":"30","author":"KJ Buster","year":"2012","unstructured":"Buster KJ, Stevens EI, Elmets CA (2012) Dermatologic health disparities. Dermatol Clin 30(1):53\u201359","journal-title":"Dermatol Clin"},{"issue":"2","key":"2533_CR15","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jaad.2014.03.013","volume":"71","author":"CL Chen","year":"2014","unstructured":"Chen CL, Fitzpatrick L, Kamel H (2014) Who uses the emergency department for dermatologic care? A statewide analysis. J Am Acad Dermatol 71(2):308\u2013313","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2533_CR16","first-page":"59","volume":"15","author":"T Gilkey","year":"2022","unstructured":"Gilkey T, Trinidad J, Kovalchin C, Minta A, Rosenbach M, Kaffenberger BH (2022) Defining drugs that are high-risk associations for drug reactions within the hospital setting. J Clin Aesthetic Dermatol 15(6):59","journal-title":"J Clin Aesthetic Dermatol"},{"key":"2533_CR17","doi-asserted-by":"crossref","unstructured":"Krueger J, Puig L, Tha\u00e7i D (2022) Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol 1\u201314.","DOI":"10.1007\/s40257-021-00658-9"},{"issue":"9","key":"2533_CR18","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/1744666X.2019.1648209","volume":"15","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Van Voorhees AS, Lebwohl MG (2019) An update on generalized pustular psoriasis. Expert Rev Clin Immunol 15(9):907\u2013919","journal-title":"Expert Rev Clin Immunol"},{"issue":"12","key":"2533_CR19","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1038\/jid.2015.296","volume":"135","author":"J Takeshita","year":"2015","unstructured":"Takeshita J, Gelfand JM, Li P, Pinto L, Yu X, Rao P, Doshi JA (2015) Psoriasis in the US Medicare population: prevalence, treatment, and factors associated with biologic use. J Investigative Dermatol 135(12):2955\u20132963","journal-title":"J Investigative Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-023-02533-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-023-02533-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-023-02533-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T16:06:07Z","timestamp":1689177967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-023-02533-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["2533"],"URL":"https:\/\/doi.org\/10.1007\/s00403-023-02533-5","relation":{},"ISSN":["1432-069X"],"issn-type":[{"type":"electronic","value":"1432-069X"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"assertion":[{"value":"1 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Benjamin Kaffenberger is an investigator for AnaptysBio, Biogen, InflaRx, OnQuality Pharmaceuticals and the Dermatology Foundation","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}